MyVisionNCT07463521
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 29 → 36 locations
- Minor Trial sites expanded: 14 → 29 locations
- Minor Study sites: 14 to 15
- Notable Eligibility criteria expanded, about 23 words
- Trial sites expanded: 11 → 14 locations
- Secondary endpoints: details revised at 6 of 7 entries
- Minor Trial sites expanded: 7 → 11 locationsv5
- Minor Trial sites expanded: 2 → 7 locationsv4
- Notable Recruitment opened
- Study sites: 0 to 2
- Start date changed from estimate of May 29, 2026 to May 27, 2026
- Minor Study title revisedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
After the Screening Period, participants will enter the study Intervention Period and will be administered study drug for up to 6 weeks. Prior to entering the Intervention Period, study participants will be randomized at a 1:1 ratio and will receive rozanolixizumab. At the End of Treatment Visit, participants will enter an Observation Period of 4 to 7 weeks with an opportunity to transition to an open-label extension study.
After the Screening Period, participants will enter the study Intervention Period and will be administered study drug for up to 6 weeks. Prior to entering the Intervention Period, study participants will be randomized at a 1:1 ratio and will receive placebo. At the End of Treatment Visit, participants will enter an Observation Period of 4 to 7 weeks with an opportunity to transition to an open-label extension study.
Drugs: Rozanolixizumab, Placebo
Sites
36 sites in 9 countries
China 7, Spain 7, United States 6, France 5, Poland 4, Japan 3, Georgia 2, Canada 1, Germany 1